CarthaGenetics for EU
market development of
CarthaGenetics® announced today that it had signed an agreement with the Australian company race Oncology to expedite the launch of the company’s Named Patient Program (NPP) in Europe, and to distribute and sell Bisantrene under the program. Under the agreement, CarthaGenetics® will be responsible for market development and awareness of Bisantrene prior to launch and all necessary regulatory approvals to allow Bisantrene to be sold in each target NPP country. CarthaGenetics® will also be responsible for all storage, distribution, invoicing, sales and customer service of Bisantrene in each country under the Named Patient Program. CarthaGenetics® Founder and CEO, Philippe Carteron de Balmont, said: “At CarthaGenetics, we are proud to help Race Oncology launch Bisantrene and achieve success in the European market. Named Patient access regulations in individual European countries allow patients access to innovative therapies under development. Given Bisantrene’s safety profile and clinical data, it is well-suited to a Named Patient sales Program in those countries”. The agreement will also provide Race with all the infrastructure and logistical support needed to sell Bisantrene in various European countries. In all markets outside Europe, Race Oncology is now actively pursuing licensees for Bisantrene. “CarthaGenetics are experts in Named Patient Program sales in Europe,” said Managing Director, Peter Molloy. “Their expertise will help ensure Bisantrene gets to market rapidly and achieves its full sales potential.” To that end, both companies will be attending the BioPharm America conference in Boston on 13-15 September, 2016. For more information, contact: firstname.lastname@example.org
CarthaGenetics® will be attending Refresh Europe 2016 in Paris, France, on November 24th, 2016. Organized by Labiotech, this is Europe’s most refreshing biotech conference in its second edition.Come to get a deep insight into tomorrow's Biotech trends in a dynamic and modern way, and meet with 250 of Europe's Biotech leaders, innovators and enthusiasts. To arrange a short meeting with us at the event, please contact Philippe Carteron de Balmont, CEO, at: email@example.com and connect to this event at: http://labiotech.eu/refresh/
CarthaGenetics® will be attending BIO-Europe 2016 in Cologne, Germany, on November 7-9th, 2016. This is the 22nd annual BIO-Europe event, the largest biotechnology partnering conference held in Europe. Over 3,500 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and deal makers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners.BIO-Europe features the industry’s most advanced....